Gutiérrez-Hernández Juan-Carlos, Caffey Sean, Abdallah Walid, Calvillo Phillip, González Roberto, Shih Jason, Brennan Jeff, Zimmerman Jenna, Martínez-Camarillo Juan-Carlos, Rodriguez Anthony R, Varma Rohit, Santos Arturo, Sánchez Gisela, Humayun Mark
Doheny Eye Institute, Los Angeles, CA ; Centro de Retina Médica y Quirúrgica, SC, Zapopan, Jalisco, Mexico.
Replenish Inc., Pasadena, CA.
Transl Vis Sci Technol. 2014 Jul 1;3(4):8. doi: 10.1167/tvst.3.3.8. eCollection 2014 May.
To determine the feasibility of the surgical procedure and to collect some safety data regarding the bioelectronics of a novel micro drug pump for intravitreal drug delivery in a Beagle dog model for up to 1 year.
Thirteen Beagle dogs were assigned to two groups. The experimental group ( = 11) underwent pars plana implantation of MicroPump; the body of which was sutured episclerally, while its catheter was secured at a pars plana sclerotomy. The control group ( = 2) underwent sham surgeries in the form of a temporary suturing of the MicroPump, including placement of the pars plana tube. Baseline and follow-up exams included ophthalmic examination and imaging. The experimental animals were euthanized and explanted at predetermined time points after surgery (1, 3, and 12 months), while the control animals were euthanized at 3 months. All operated eyes were submitted for histopathology.
Eyes were scored according to a modified McDonald-Shadduck system and ophthalmic imaging. Neither the implanted eyes nor the control eyes showed clinically significant pathological changes beyond the expected surgical changes. The operated eyes showed neither significant inflammatory reaction nor tissue ingrowth through the sclerotomy site compared with the fellow eyes.
This study shows that the Replenish Posterior MicroPump could be successfully implanted with good safety profile in this animal model.
The results of this study in a Beagle dog model are supportive of the biocompatibility of Replenish MicroPump and pave the way to the use of these devices for ocular automated drug delivery after further testing in larger animal models.
确定手术操作的可行性,并收集有关一种新型微型药物泵生物电子学的安全性数据,该药物泵用于在比格犬模型中进行玻璃体内药物递送,为期长达1年。
13只比格犬被分为两组。实验组(n = 11)接受了MicroPump的扁平部植入;其主体通过巩膜外缝合固定,而其导管则固定在扁平部巩膜切开处。对照组(n = 2)接受了以临时缝合MicroPump形式的假手术,包括放置扁平部导管。基线和随访检查包括眼科检查和成像。实验动物在手术后的预定时间点(1、3和12个月)实施安乐死并取出植入物,而对照动物在3个月时实施安乐死。所有手术眼均进行组织病理学检查。
根据改良的McDonald-Shadduck系统和眼科成像对眼睛进行评分。植入眼和对照眼均未显示出超出预期手术变化的具有临床意义的病理变化。与对侧眼相比,手术眼既未显示出明显的炎症反应,也未显示出组织通过巩膜切开部位向内生长。
本研究表明,Replenish Posterior MicroPump可以在该动物模型中成功植入,且安全性良好。
本研究在比格犬模型中的结果支持Replenish MicroPump的生物相容性,并为在更大动物模型中进行进一步测试后将这些装置用于眼部自动药物递送铺平了道路。